OTC · PHCG
Pure Harvest Corporate Group, Inc.
$0.02-$0.00 (-6.84%)
Pure Harvest Corporate Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.13% below the high.
Loading market information…
OTC · SQZB · USD
Stock price, earnings
Quote as of Oct 28, 2026, 03:17 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
SQZ Biotechnologies Company’s quoted price sits in the lower half of its reported 52-week range, 65.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
SQZ Biotechnologies Company’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.58. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow SQZ Biotechnologies Company’s reporting calendar.
THE COMPANY BEHIND THE TICKER
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Aug 4, 2022 | -$0.78-2.53% vs estimate | $3.20M-18.2% vs estimate |
|---|
| Q1 2022 | May 10, 2022 | -$0.75-9.49% vs estimate | $2.87M-41.74% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.02-$0.00 (-6.84%)
Pure Harvest Corporate Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.13% below the high.
$0.04-$0.01 (-13.51%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
A$0.00A$0.00 (0.0%)
Biotron Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
$3.29$0.00 (0.0%)
Helix BioMedix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.38% below the high.
$0.06$0.00 (0.0%)
SYBLEU Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.05$0.00 (0.0%)
Orgenesis Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.87% below the high.
$0.01$0.00 (0.0%)
Viracta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.8% below the high.
$0.00$0.00 (0.0%)
Indocan Resources Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
